Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Liver Adiposity Effects on Pediatric Statin
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 50
- Registration Number
- NCT04903223
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT04889287
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04887194
- Locations
- 🇺🇸
Goshen Health, Goshen, Indiana, United States
🇺🇸MultiCare Health System, Tacoma, Washington, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 220
- Registration Number
- NCT04883840
- Locations
- 🇧🇪
Imelda Ziekenhuis, Bonheiden, Antwerp, Belgium
🇧🇪UZ Leuven, Leuven, Vlaams-Brabant, Belgium
Supplements, Placebo, or Rosuvastatin Study
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 203
- Registration Number
- NCT04846231
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Khanh Nguyen
- Target Recruit Count
- 30
- Registration Number
- NCT04833764
- Locations
- 🇺🇸
VA Portland Health Care System (VAPORHCS), Portland, Oregon, United States
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 582
- Registration Number
- NCT04826354
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Anam Hospital, Seoul, Korea, Republic of
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 424
- Registration Number
- NCT04824911
- Locations
- 🇨🇳
Yenchu Huang, Chiayi City, Taiwan
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 65
- Registration Number
- NCT04817904
- Locations
- 🇪🇬
Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine, Cairo, Egypt
A Study of Lasmiditan in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT04749914
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.